Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 1/20 | 0.42 |
| ▸ | MB | P02144 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydantoin SCHEMBL7285865 | 0.87 | — | — | |
| Hydantoin SCHEMBL27705088 | 0.87 | CRBN (0.52) | CRBNMB | |
| Hydantoin SCHEMBL27690 | 0.87 | — | — | |
| Hydantoin SCHEMBL3479397 | 0.84 | — | — | |
| Hydantoin SCHEMBL8639680 | 0.84 | — | — | |
| Hydantoin SCHEMBL1786052 | 0.84 | — | — | |
| Hydantoin SCHEMBL2224461 | 0.84 | — | — | |
| Hydantoin SCHEMBL10770473 | 0.84 | — | — | |
| Hydantoin SCHEMBL3246334 | 0.84 | — | — | |
| Hydantoin SCHEMBL10578141 | 0.84 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1807440-B1 | NOVOBIOCIN ANALOGUES AS ANTICANCER AGENTS | UNIV KANSAS (US) | 2020-02-19 | — | — | EP | disclosed |
| EP-2438078-B1 | NOVOBIOCIN ANALOGUES HAVING MODIFIED SUGAR MOIETIES | UNIV KANSAS (US) | 2017-10-25 | — | — | EP | disclosed |
| US-9120774-B2 | Novobiocin analogues having modified sugar moieties | UNIVERSITY OF KANSAS (US) | 2015-09-01 | — | — | US | disclosed |
| US-20120252745-A1 | NOVOBIOCIN ANALOGUES HAVING MODIFIED SUGAR MOIETIES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-10-04 | — | — | US | disclosed |
| US-8212011-B2 | Novobiocin analogues | UNIVERSITY OF KANSAS (US) | 2012-07-03 | — | — | US | disclosed |
| US-8212012-B2 | Novobiocin analogues having modified sugar moieties | UNIVERSITY OF KANSAS (US) | 2012-07-03 | — | — | US | disclosed |
| EP-2438078-A1 | NOVOBIOCIN ANALOGUES HAVING MODIFIED SUGAR MOIETIES | UNIVERSITY OF KANSAS (US) | 2012-04-11 | — | — | EP | disclosed |
| US-7960353-B2 | Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders | UNIVERSITY OF KANSAS (US) | 2011-06-14 | — | — | US | disclosed |
| US-7811998-B2 | Novobiocin analogues as anticancer agents | UNIVERSITY OF KANSAS (US) | 2010-10-12 | — | — | US | disclosed |
| WO-2010096650-A1 | NOVOBIOCIN ANALOGUES HAVING MODIFIED SUGAR MOIETIES | UNIVERSITY OF KANSAS (US) | 2010-08-26 | — | — | WO | disclosed |
| WO-2006050501-A2 | NOVOBIOCIN ANALOGUES AS ANTICANCER AGENTS | UNIVERSITY OF KANSAS (US) | 2006-05-11 | — | — | WO | disclosed |
| US-5436260-A | Substituted 1-benzylimidazole-5-methylidene hydantoins | WARNER-LAMBERT COMPANY (US) | 1995-07-25 | — | — | US | disclosed |
| US-5308853-A | Hypotensive agents, antagonists of angiotensin II | WARNER-LAMBERT COMPANY (US) | 1994-05-03 | — | — | US | disclosed |
| WO-1993013077-A1 | ANGIOTENSIN II RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1993-07-08 | — | — | WO | disclosed |
| US-4145510-A | AS STARTING MATERIAL IN A FLAMEPROOF POLYURETHANE | CIBA-GEIGY CORPORATION (US) | 1979-03-20 | — | — | US | disclosed |
| US-4145510-A | AS STARTING MATERIAL IN A FLAMEPROOF POLYURETHANE | CIBA-GEIGY CORPORATION (US) | 1979-03-20 | — | — | US | disclosed |
| US-4138569-A | FIRE RETARDANT EPOXY RESINS, POLYESTERS AND POLYURETHANES | CIBA-GEIGY CORPORATION (US) | 1979-02-06 | — | — | US | disclosed |
| US-4138569-A | FIRE RETARDANT EPOXY RESINS, POLYESTERS AND POLYURETHANES | CIBA-GEIGY CORPORATION (US) | 1979-02-06 | — | — | US | disclosed |
| US-4093809-A | INTERMEDIATES IN PREPARING FLAME-RETARDANT POLYESTERS AND POLYURETANES | CIBA-GEIGY CORPORATION (US) | 1978-06-06 | — | — | US | disclosed |
| US-4093809-A | INTERMEDIATES IN PREPARING FLAME-RETARDANT POLYESTERS AND POLYURETANES | CIBA-GEIGY CORPORATION (US) | 1978-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120252745-A1 | NOVOBIOCIN ANALOGUES HAVING MODIFIED SUGAR MOIETIES | HSP90AB1, HSP90AB2P, HSP90B1 | CRBN 4105/4885MB 1563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.